Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0 ~ 102.0% Factory

Apejuwe kukuru:

Orukọ Kemikali: Lenvatinib Mesylate

CAS: 857890-39-2

Ayẹwo: 98.0 ~ 102.0%

Irisi: Funfun si Paa-White Powder tabi Awọn kirisita

Olubasọrọ: Dokita Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Alaye ọja

Jẹmọ Products

ọja Tags

Apejuwe:

Kemikali Properties:

Orukọ Kemikali Lenvatinib Mesylate
Awọn itumọ ọrọ sisọ 4- [3-Chloro-4-[(cyclopropylaminocarbonyl) amino] phenoxy] -7-Methoxy-6-Quinolinecarboxamide Mesylate;E 7080 Mesylate;Lenvima
Nọmba CAS 857890-39-2
NỌMBA CAT RF-PI1975
Iṣura Ipo Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu
Fọọmu Molecular C21H19N4O4Cl.CH4O3S
Òṣuwọn Molikula 522.96
Brand Ruifu Kemikali

Awọn pato:

Nkan Awọn pato
Ifarahan Funfun si Paa-White Powder tabi kirisita
Idanimọ Nipasẹ IR;Nipasẹ UV;Nipasẹ HPLC
Solubility Tiotuka die-die ninu Omi, Ailesolusan Ni Ethanol
Ojuami Iyo 228.0 ~ 230.0 ℃
Akoonu Omi (KF) <1.00%
Aloku lori Iginisonu <0.10%
Awọn irin Heavy <20ppm
Awọn nkan ti o jọmọ
Eyikeyi Nikan Aimọ <0.50%
Lapapọ Awọn Aimọ <1.00%
Aseyori / Analysis Ọna 98.0 ~ 102.0% (HPLC Ipilẹ lori Gbigbe)
Olopobobo iwuwo 0.40gm/ml ~0.60gm/ml
Igbeyewo Standard Standard Enterprise
Lilo API

Package & Ibi ipamọ:

Package: Igo, apo bankanje aluminiomu, 25kg / Paali ilu, tabi gẹgẹ bi ibeere alabara

Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin

Awọn anfani:

1

FAQ:

Ohun elo:

Lenvatinib Mesylate (CAS: 857890-39-2) jẹ inhibitor oral ati olona-fojusi ti VEGFR1-3, FGFR1-4, PDGFR, KIT, ati RET, pẹlu awọn iṣẹ antitumor ti o lagbara.Lenvatinib Mesylate jẹ oludena tyrosine kinase (RTK) olugba ti o ni yiyan fun VEGFR2.O ṣe afihan iṣẹ-ṣiṣe antineoplastic, ati pe o ti ni itọkasi fun itọju awọn alaisan ti o ni atunṣe ti agbegbe tabi metastatic, ilọsiwaju, iodine radioactive (RAI) -refractory differentiated tairodu akàn.Lenvatinib Mesylate ni akọkọ fọwọsi nipasẹ Ile-iṣẹ Ounje ati Oògùn AMẸRIKA (FDA) ni Oṣu kejila ọjọ 13, ọdun 2015, lẹhinna fọwọsi nipasẹ Ile-iṣẹ elegbogi ati Awọn Ẹrọ Iṣoogun ti Japan (PMDA) ni Oṣu Kẹta Ọjọ 26, Ọdun 2015, ati fọwọsi nipasẹ Ile-iṣẹ Oogun Yuroopu (EMA) lori Oṣu Karun ọjọ 28, Ọdun 2015. O jẹ idagbasoke ati tita bi Lenvima® nipasẹ Eisai.Lenvatinib Mesylate jẹ inhibitor ọpọ olugba tyrosine kinase ti oral pẹlu ipo abuda alailẹgbẹ kan ti o yan ni idinamọ awọn iṣẹ ṣiṣe kinase ti awọn olugba idagba endothelial ti iṣan (VEGF), ni afikun si awọn proangiogenic miiran ati awọn ọna oncogenic ti o ni ibatan tyrosine kinases ro pe o ni ipa ninu isunmọ tumo. .O ti wa ni itọkasi fun awọn itọju ti ilọsiwaju radioiodine-refractory differentiated tairodu akàn.Lenvimani a lo funrararẹ lati ṣe itọju akàn tairodu ti o yatọ (DTC), iru akàn tairodu ti ko le ṣe itọju pẹlu iodine ipanilara ati ti nlọsiwaju.LENVIMA ni a lo pẹlu oogun miiran ti a npe ni everolimus lati tọju awọn agbalagba ti o ni iru akàn kidinrin kan ti a npe ni carcinoma kidirin ti ilọsiwaju (RCC) lẹhin itọju kan pẹlu oogun egboogi-akàn miiran.

Kọ ifiranṣẹ rẹ nibi ki o si fi si wa